4.7 Article

Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 210, Issue 13, Pages 2813-2821

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20131244

Keywords

-

Funding

  1. Agence Nationale de Recherche sur le Sida
  2. Sidaction
  3. AREVA Foundation
  4. Vaccine Research Institute
  5. Labex IBEID program
  6. FP7 program HIT Hidden HIV [Health-F3-2012-305762]
  7. Institut Pasteur
  8. Fonds de dotation Pierre Berge
  9. Fondation pour la Recherche Medicale
  10. Milieu Interieur program [ANR-10-LABX-69-01]
  11. Bill and Melinda Gates Foundation [38619s]
  12. Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery [AI 100663-01]

Ask authors/readers for more resources

The neutralizing activity of anti-HIV-1 antibodies is typically measured in assays where cell-free virions enter reporter cell lines. However, HIV-1 cell to cell transmission is a major mechanism of viral spread, and the effect of the recently described broadly neutralizing antibodies (bNAbs) on this mode of transmission remains unknown. Here we identify a subset of bNAbs that inhibit both cell-free and cell-mediated infection in primary CD4(+) lymphocytes. These antibodies target either the CD4-binding site (NIH45-46 and 3BNC60) or the glycan/V3 loop (10-1074 and PGT121) on HIV-1 gp120 and act at low concentrations by inhibiting multiple steps of viral cell to cell transmission. These antibodies accumulate at virological synapses and impair the clustering and fusion of infected and target cells and the transfer of viral material to uninfected T cells. In addition, they block viral cell to cell transmission to plasmacytoid DCs and thereby interfere with type-I IFN production. Thus, only a subset of bNAbs can efficiently prevent HIV-1 cell to cell transmission, and this property should be considered an important characteristic defining antibody potency for therapeutic or prophylactic antiviral strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available